Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 1/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | CLK1 | P49759 | 2/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29800237 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2EGFRRECQLHIF1APDGFRB | |
| SCHEMBL1959494 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2EGFRRECQLHIF1APDGFRB | |
| SCHEMBL31060645 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2EGFRRECQLHIF1APDGFRB | |
| Hydrochloric Acid SCHEMBL1957337 | 0.99 | SMN1; SMN2 (0.98) | SMN1; SMN2EGFRRECQLHIF1APDGFRB | |
| Hydrochloric Acid SCHEMBL1957339 | 0.99 | SMN1; SMN2 (0.98) | SMN1; SMN2EGFRRECQLHIF1APDGFRB | |
| SCHEMBL6782221 | 0.90 | EGFR (0.82) | SMN1; SMN2EGFRRECQLHIF1APDGFRB | |
| SCHEMBL6782225 | 0.90 | EGFR (0.82) | SMN1; SMN2EGFRRECQLHIF1APDGFRB | |
| SCHEMBL6782228 | 0.90 | EGFR (0.82) | SMN1; SMN2EGFRRECQLHIF1APDGFRB | |
| SCHEMBL17232854 | 0.90 | EGFR (0.82) | SMN1; SMN2EGFRRECQLHIF1APDGFRB | |
| SCHEMBL17232864 | 0.87 | SMN1; SMN2 (0.77) | SMN1; SMN2EGFRRECQLHIF1APDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577832-A1 | METHOD FOR PREDICTING THE RESPONSE TO AN INHIBITOR OF EGFR KINASE ACTIVITY | Indivumed GmbH (DE) | 2025-07-02 | — | — | EP | claimed |
| US-12036218-B2 | Modulators of airway basal cells for the treatment or prevention of lung diseases | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e. V. (DE) | 2024-07-16 | — | — | US | claimed |
| US-11478477-B2 | Method for treating cancer by combination of FAK/ALK/ROS1 inhibitor and EGFR inhibitor | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-10-25 | — | — | US | claimed |
| US-11390600-B2 | Crystalline forms of C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. (US) | 2022-07-19 | — | — | US | claimed |
| EP-4011376-A2 | COMBINATION OF AN ALK INHIBITOR AND AN EGFR INHIBITOR FOR TREATING CANCER | Ascentage Pharma (Suzhou) Co., Ltd. (CN) | 2022-06-15 | — | — | EP | claimed |
| US-20200339531-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | VERTEX PHARMACEUTICALS INCORPORATED | 2020-10-29 | — | — | US | claimed |
| US-10738027-B2 | Crystalline forms of C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. (US) | 2020-08-11 | — | — | US | claimed |
| US-20190127348-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. | 2019-05-02 | — | — | US | claimed |
| EP-2332905-B1 | BCRP/ABCG2 Inhibitor | YAKULT HONSHA KK (JP) | 2017-03-01 | — | — | EP | claimed |
| WO-2015095807-A1 | CANCER TREATMENTS USING COMBINATIONS OF EGFR AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2015-06-25 | — | — | WO | claimed |
| EP-2332905-A1 | BCRP/ABCG3 Inhibitor | Kabushiki Kaisha Yakult Honsha (JP) | 2011-06-15 | — | — | EP | claimed |
| US-20090253656-A1 | BCRP/ABCG2 INHIBITOR | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2009-10-08 | — | — | US | claimed |
| EP-1864972-A1 | BCRP/ABCG2 INHIBITOR | Kabushiki Kaisha Yakult Honsha (JP) | 2007-12-12 | — | — | EP | claimed |
| US-5302606-A | Administering to inhibit cell proliferation | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1994-04-12 | — | — | US | claimed |
| EP-0525109-A4 | STYRYL-SUBSTITUTED MONOCYCLIC AND BICYCLIC HETEROARYL COMPOUNDS WHICH INHIBIT EGF RECEPTOR TYROSINE KINASE | — | 1993-06-30 | — | — | EP | claimed |
| EP-0525109-A1 | STYRYL-SUBSTITUTED MONOCYCLIC AND BICYCLIC HETEROARYL COMPOUNDS WHICH INHIBIT EGF RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1993-02-03 | — | — | EP | claimed |
| WO-1991016051-A1 | STYRYL-SUBSTITUTED MONOCYCLIC AND BICYCLIC HETEROARYL COMPOUNDS WHICH INHIBIT EGF RECEPTOR TYROSINE KINASE | RHÔNE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1991-10-31 | — | — | WO | claimed |
| US-20260000714-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-0525109-A1 | STYRYL-SUBSTITUTED MONOCYCLIC AND BICYCLIC HETEROARYL COMPOUNDS WHICH INHIBIT EGF RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1993-02-03 | — | — | EP | disclosed |
| WO-1991016051-A1 | STYRYL-SUBSTITUTED MONOCYCLIC AND BICYCLIC HETEROARYL COMPOUNDS WHICH INHIBIT EGF RECEPTOR TYROSINE KINASE | RHÔNE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1991-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127348-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | SMN1; SMN2 3040/4885EGFR 569/4885RECQL 610/4885 |
| US-20090253656-A1 | BCRP/ABCG2 INHIBITOR | ABCC1, ABCB1, BRCA1 | SMN1; SMN2 4826/4885EGFR 830/4885RECQL 363/4885 |
| US-20260000714-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS | KIT, CPA3, MKI67 | SMN1; SMN2 1652/4885EGFR 3015/4885RECQL 3924/4885 |
| US-10738027-B2 | Crystalline forms of C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | SMN1; SMN2 3040/4885EGFR 569/4885RECQL 610/4885 |
| US-11478477-B2 | Method for treating cancer by combination of FAK/ALK/ROS1 inhibitor and EGFR inhibitor | ROS1, ALK, PTK2 | SMN1; SMN2 4116/4885EGFR 5/4885RECQL 4042/4885 |
| US-20200339531-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | SMN1; SMN2 3040/4885EGFR 569/4885RECQL 610/4885 |
| US-11390600-B2 | Crystalline forms of C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | SMN1; SMN2 3040/4885EGFR 569/4885RECQL 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.